Why calling it therapy is a legal problem in Oregon

Last reviewed: August 2026 · Psychedelic law changes quickly — verify current status before relying on this page.

For licensed psilocybin service centers, facilitators, and marketing professionals who want to understand exactly why Oregon’s regulatory framework prohibits using the word “therapy” to describe psilocybin services — and what the practical consequences of that prohibition are.

The short answer

Oregon’s psilocybin program is a regulated wellness service model, not a clinical therapy model. OAR 333-333-6040 prohibits licensed service centers and facilitators from using the words “therapy” or “therapeutic” to describe their psilocybin services in marketing and communications. The prohibition is not a technicality — it reflects a deliberate structural choice embedded in Measure 109 and the OPS rulemaking process. Calling what a service center offers “psilocybin-assisted therapy” or “psychedelic therapy” misrepresents the nature of the service in ways that create regulatory exposure, client confusion, and potential civil liability. The prohibition also creates a communication challenge, because the broader public and media routinely use those terms. Understanding why the prohibition exists and how to communicate around it is essential for any psychedelic business operating in Oregon.

The structural reason for the prohibition

Oregon’s Measure 109, as implemented through ORS 475A and OAR 333-333, created a facilitation model specifically to distinguish what licensed facilitators do from what licensed therapists and other healthcare providers do. This distinction was deliberate and consequential for multiple reasons.

Calling psilocybin services “therapy” implies a clinical treatment relationship — a relationship in which a trained therapist applies therapeutic techniques to treat a diagnosed condition. Oregon’s facilitation model involves neither diagnosis nor clinical treatment. Facilitators are not required to hold any clinical license. The relationship between a facilitator and a client is a supported wellness relationship, not a therapeutic or clinical one. The OPS-mandated informed consent document states this explicitly: psilocybin services are not medical or clinical treatment.

If service centers were permitted to market their services as therapy, clients would reasonably expect those services to operate under the same standards as licensed therapy — clinical assessment, treatment planning, evidence-based interventions, professional liability standards, and health insurance billing. None of these apply to OPS-licensed facilitation. Permitting the therapy label while operating under a facilitation model creates a fundamental mismatch between the client’s reasonable expectation and the actual service being provided — which is why OPS treats it as a misleading representation under OAR 333-333-6040.

The specific terms that are prohibited

OAR 333-333-6040 prohibits using language that represents psilocybin services as a “medical, psychiatric, or clinical therapy” or implies that the service is a medical treatment. The prohibition covers: “therapy,” “therapeutic,” “psychotherapy,” “psilocybin-assisted therapy,” “psychedelic-assisted therapy,” “psychedelic therapy,” and analogous terms that convey a clinical or therapeutic treatment relationship.

The prohibition applies to marketing and external communications — the service center’s website, social media accounts, advertising, email communications, printed materials, and verbal descriptions in sales or intake conversations. It does not prohibit clients, journalists, or researchers from using those terms — it prohibits the service center and facilitators from using them in describing their own services.

The prohibition also applies regardless of whether the facilitator actually holds a clinical license. A dual-licensed therapist-facilitator who describes their psilocybin facilitation services as “therapy sessions” in marketing has violated OAR 333-333-6040 even if they legitimately provide clinical therapeutic services in a separate professional context. The marketing prohibition applies to the facilitation service, not to the facilitator’s other professional work.

What is not prohibited

The prohibition targets how service centers and facilitators describe their own services — it does not prohibit:

Accurately describing the facilitator’s background as a licensed therapist or clinical professional, provided the description makes clear that the facilitation service itself is not therapy.

Referencing the scientific literature that uses the phrase “psilocybin-assisted therapy” or “psychedelic-assisted therapy,” provided the reference makes clear that the research terminology describes controlled trial conditions rather than the specific service being offered.

Using terms like “supportive,” “non-directive,” “preparation and integration,” “guided,” and similar language that accurately describes the facilitation model without implying clinical therapy.

Discussing what integration support means and how the service center approaches the preparation and integration sessions — including that integration sessions may involve processing the psilocybin experience in a supportive, non-directive conversation with the facilitator.

Accurately describing the HB 2387 dual licensure framework, which allows dual-licensed clinicians to provide clinical services during preparation and integration sessions, provided the description makes clear that the administration session itself is not a clinical therapy session.

The communication challenge

The therapy prohibition creates a genuine communication challenge for psychedelic businesses. “Psilocybin-assisted therapy” is the dominant phrase in academic literature, journalism, and public discourse about psilocybin. Many prospective clients arrive at a service center’s website already having read about “psychedelic therapy” and expecting that term to describe what they will receive. A service center that avoids the term without explanation may confuse prospective clients who are looking for the thing they read about.

The practical communication solution is transparency rather than avoidance. A service center can explain directly — on its website, in its intake materials, in its marketing — what the OPS facilitation model is and how it differs from a clinical therapy model. This kind of transparent explanation does two things: it complies with OPS rules by not misrepresenting the service, and it educates prospective clients so they understand what they are accessing before they commit. A client who understands the difference between a clinical therapy relationship and a supported wellness facilitation relationship before their preparation session is better positioned to have a useful experience than one who discovers the difference mid-session.

Consequences of violating the prohibition

A service center or facilitator who uses prohibited therapy language in their marketing faces OPS discipline under OAR 333-333-6040. OPS can investigate, issue warnings, impose civil penalties, and — for repeated or egregious violations — take license action. The prohibition is not merely advisory; it is an enforceable rule.

A service center whose marketing uses therapy language may also face civil liability under Oregon’s Unlawful Trade Practices Act (ORS 646.605–656) if a client can show they relied on that language in a way that caused them harm — for example, a client who accessed psilocybin services expecting clinical therapy protections that did not apply, and who suffered harm as a result. The UTPA minimum statutory damage of $200 per violation plus attorney fees makes such claims economically viable for plaintiffs.

A client who approaches a psilocybin session with clinical therapy expectations — and who is then harmed — may also argue in a negligence claim that the service center’s own marketing induced those expectations, which contributed to their harm. The connection between marketing language and client expectations becomes part of the liability analysis in this type of case.

Dual-licensed facilitators and the communication nuance

A facilitator who holds both an OPS facilitator license and a clinical therapy license regulated by one of HB 2387’s seven boards faces a specific communication nuance. Under HB 2387, this facilitator can provide clinical therapeutic services during preparation and integration sessions. But they cannot market the administration session as therapy, and they must be careful in their overall marketing to distinguish their clinical professional services from their OPS facilitation services.

A dual-licensed facilitator might appropriately describe their services as: “Licensed therapist offering psilocybin facilitation through Oregon’s licensed program, with therapeutic preparation and integration support.” That description is accurate — it identifies the clinical credential, the facilitation license, and the distinction between what happens in preparation and integration (therapeutic support) and what happens in the administration session (facilitation). A description that simply says “psilocybin-assisted therapy by a licensed therapist” collapses that distinction in a way OAR 333-333-6040 prohibits.

When public information may be enough

OAR 333-333-6040 is publicly available through the Oregon Secretary of State’s administrative rules database. OPS has published FAQ guidance on marketing compliance at oregon.gov/psilocybin. Oregon’s UTPA (ORS 646.605–656) is available through the Oregon Legislative Assembly.

When you should speak with a lawyer

A service center that has been using therapy language in its marketing and wants to transition to compliant language should consult an attorney about both the remediation and about whether the prior use has created any pending exposure. A service center that has received an OPS inquiry about its marketing claims should retain counsel before responding. A dual-licensed facilitator who wants to accurately describe both their clinical credentials and their facilitation services in marketing that complies with OAR 333-333-6040 should have that language reviewed by an attorney before publishing it.

You might also want to read

• What psychedelic businesses can and cannot say in marketing
• Health claims, testimonials, and FTC rules for psychedelic services
• What facilitators and service centers can say about outcomes
• Dual licensure: what HB 2387 changed for Oregon clinician-facilitators
• What healthcare professionals should consider before entering the psychedelic space